|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SAMD9L |
Gene summary for SAMD9L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SAMD9L | Gene ID | 219285 |
| Gene name | sterile alpha motif domain containing 9 like | |
| Gene Alias | ATXPC | |
| Cytomap | 7q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IVG5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 219285 | SAMD9L | LZE20T | Human | Esophagus | ESCC | 1.23e-07 | 4.05e-01 | 0.0662 |
| 219285 | SAMD9L | LZE24T | Human | Esophagus | ESCC | 3.89e-13 | 5.14e-01 | 0.0596 |
| 219285 | SAMD9L | LZE6T | Human | Esophagus | ESCC | 7.85e-03 | 1.84e-01 | 0.0845 |
| 219285 | SAMD9L | P1T-E | Human | Esophagus | ESCC | 7.11e-03 | 2.91e-01 | 0.0875 |
| 219285 | SAMD9L | P2T-E | Human | Esophagus | ESCC | 6.71e-22 | 4.45e-01 | 0.1177 |
| 219285 | SAMD9L | P5T-E | Human | Esophagus | ESCC | 2.10e-04 | 7.25e-02 | 0.1327 |
| 219285 | SAMD9L | P8T-E | Human | Esophagus | ESCC | 7.57e-18 | 4.06e-01 | 0.0889 |
| 219285 | SAMD9L | P9T-E | Human | Esophagus | ESCC | 1.16e-05 | 1.85e-01 | 0.1131 |
| 219285 | SAMD9L | P11T-E | Human | Esophagus | ESCC | 2.78e-10 | 5.46e-01 | 0.1426 |
| 219285 | SAMD9L | P20T-E | Human | Esophagus | ESCC | 1.15e-08 | 3.43e-01 | 0.1124 |
| 219285 | SAMD9L | P21T-E | Human | Esophagus | ESCC | 6.14e-07 | 2.19e-01 | 0.1617 |
| 219285 | SAMD9L | P23T-E | Human | Esophagus | ESCC | 1.07e-09 | 3.13e-01 | 0.108 |
| 219285 | SAMD9L | P24T-E | Human | Esophagus | ESCC | 4.29e-08 | 2.13e-01 | 0.1287 |
| 219285 | SAMD9L | P26T-E | Human | Esophagus | ESCC | 1.52e-02 | 9.21e-02 | 0.1276 |
| 219285 | SAMD9L | P27T-E | Human | Esophagus | ESCC | 3.90e-02 | 8.13e-02 | 0.1055 |
| 219285 | SAMD9L | P32T-E | Human | Esophagus | ESCC | 1.11e-05 | 1.54e-01 | 0.1666 |
| 219285 | SAMD9L | P36T-E | Human | Esophagus | ESCC | 3.06e-10 | 4.68e-01 | 0.1187 |
| 219285 | SAMD9L | P37T-E | Human | Esophagus | ESCC | 3.66e-06 | 2.04e-01 | 0.1371 |
| 219285 | SAMD9L | P40T-E | Human | Esophagus | ESCC | 5.80e-06 | 2.47e-01 | 0.109 |
| 219285 | SAMD9L | P47T-E | Human | Esophagus | ESCC | 2.30e-07 | 1.46e-01 | 0.1067 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SAMD9L | SNV | Missense_Mutation | c.988N>C | p.Asp330His | p.D330H | Q8IVG5 | protein_coding | deleterious(0.04) | benign(0.386) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| SAMD9L | SNV | Missense_Mutation | novel | c.801N>C | p.Met267Ile | p.M267I | Q8IVG5 | protein_coding | tolerated(0.39) | probably_damaging(0.91) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| SAMD9L | SNV | Missense_Mutation | c.3230G>T | p.Arg1077Leu | p.R1077L | Q8IVG5 | protein_coding | deleterious(0) | possibly_damaging(0.706) | TCGA-A2-A0SU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SAMD9L | SNV | Missense_Mutation | c.1432N>G | p.Thr478Ala | p.T478A | Q8IVG5 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| SAMD9L | SNV | Missense_Mutation | c.358N>C | p.Asp120His | p.D120H | Q8IVG5 | protein_coding | tolerated(0.12) | possibly_damaging(0.464) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SAMD9L | SNV | Missense_Mutation | c.963N>G | p.Phe321Leu | p.F321L | Q8IVG5 | protein_coding | deleterious(0) | benign(0.11) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SAMD9L | SNV | Missense_Mutation | c.2872N>C | p.Glu958Gln | p.E958Q | Q8IVG5 | protein_coding | deleterious(0.01) | possibly_damaging(0.488) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SAMD9L | SNV | Missense_Mutation | c.1948N>C | p.Glu650Gln | p.E650Q | Q8IVG5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SAMD9L | SNV | Missense_Mutation | rs746980471 | c.853C>T | p.Arg285Trp | p.R285W | Q8IVG5 | protein_coding | deleterious(0) | benign(0.047) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SAMD9L | SNV | Missense_Mutation | novel | c.2221N>T | p.His741Tyr | p.H741Y | Q8IVG5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |